Physician profile
Abigail Schellhammer
NPI 1508239534
$4,837.74
in general payments reported to CMS, 2019-2025
21 companies · $2,595 in 2025
The $2,595 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.44 · 2022: $35.77 · 2023: $554 · 2024: $1,555 · 2025: $2,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,598 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,598.03 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $808.70 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $595.03 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $521.16 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $499.01 | 2022-2025 | |
| Corium, LLC | $386.57 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $295.50 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $266.83 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $238.69 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $225.92 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $224.21 | 2023-2025 | Spravato |
| Alkermes, INC. | $153.17 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $127.75 | 2023-2025 | Rexulti |
| Neos Therapeutics, LP | $124.49 | 2024-2025 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $108.65 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $101.43 | 2022-2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $48.54 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $42.60 | 2024 | Quviviq |
| Almatica Pharma LLC | $19.27 | 2024 | Loreev Xr |
| Tris Pharma INC | $17.71 | 2024 | Dyanavel Xr |
| Owp Pharmaceuticals, INC. | $16.74 | 2025 | Subvenite |
| Biogen, INC. | $15.77 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Schellhammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.